Diakonie-Klinikum Schwaebisch Hall gGmbH — Clinical Trial Site

16 Registered trials

9 Currently recruiting

Organisation

Diakonie-Klinikum Schwaebisch Hall gGmbH

Location

Schwaebisch Hall, Germany

Identifier

ORG-100024041

Address

Diakoniestrasse 10, 74523, Germany

Departments

#6010: Klinik für Innere Medizin III, Onkologie, Hämatologie und Palliativmedizin
2605: Klinik für Innere Medizin III, Onkologie, Hämatologie und Palliativmedizin
Department of Gynecology
Frauenklinik
gynaecologic oncology
Gynaecology
Gynäkologie
Gynecological Oncology
Innere Abteilung
Innere Medizin III
Innere Medizin III (Tumorerkrankungen, Palliativmedizin)
Klinik für Innere Medizin III
Klinik für Neurologie und Gerontoneurologie
Onkologie, Hämatologie und Palliativmedizin

Clinical trials at this site (16)

Search interface

Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) 5
Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Newly diagnosed Multiple Myeloma in patients eligible f 5
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Recruiting

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5 2026-04-10
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Advanced Platinum-resistant Epithelial Ovarian Cancer 5 2026-04-29
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chron… Recruiting

2023-508338-33-00 Chronic Inflammatory Demyelinating Polyneuropathy 5 2024-10-01
N-PLUS Recruiting

2022-502559-69-01 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 201 4 2024-07-04
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Patients with hormone receptor positive HER2 negative l 6 2022-04-26
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended

2023-507669-24-00 Chronic lymphocytic leukemia 5 2019-11-05
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15